WSTAM
NTGN

Wilbanks Smith & Thomas Asset Management’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-600
Closed -$5K – 1499
2018
Q3 		$5K Buy
+600
New +$6.65K ﹤0.01% 1250

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's NTGN Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q4 2018, closing a stake of 600 shares — an estimated $5K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in NTGN in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 44 funds tracked by Wall St. Rank hold NTGN as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 600 Neon Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $5K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Neon Therapeutics, Inc. Common Stock position peaked at $5K in Q3 2018.
  • 44 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.